The denial conflicts with UnitedHealthcare's own published Oncology Medication Coverage Policy.
The record documents PD-L1 expression at 62% TPS and prior progression on a platinum-doublet regimen — both criteria named in §3.2 of policy UHC-MPP-PHARM-0419 (v2026.05).